Logistic regression analysis demonstrated that non-luminal subtype (odds ratio [OR]=2.059, 95% confidence interval [CI]=1.294-3.277, <i>p</i> = 0.002), elevated mSII (OR = 3.665, 95% CI = 2.235-6.010, <i>p</i> < 0.001), increased mSIRI (OR = 3.860, 95% CI = 2.350-6.338, <i>p</i> < 0.001), and reduced HALP (OR = 2.267, 95% CI = 1.411-3.643, <i>p</i> = 0.001) were independently associated with NAT efficacy.<h4>Conclusions</h4>Elevated mSII, mSIRI, and low HALP score were associated with the effectiveness of NAT in breast cancer. Here, NAT10 is linked to breast cancer.